Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 10/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29191579 | 0.80 | CA12 (0.42) | EPHX1DNM1MEN1FAAHKMT2A | |
| SCHEMBL28750661 | 0.78 | CA12 (0.40) | EPHX1DNM1MEN1FAAHKMT2A | |
| Acetic Acid SCHEMBL29288398 | 0.75 | SPHK1 (0.38) | MEN1KMT2AKDM5AKDM4CPHF8 | |
| SCHEMBL28846842 | 0.75 | SPHK1 (0.45) | DNM1MEN1KMT2A | |
| SCHEMBL6903893 | 0.75 | SPHK1 (0.45) | DNM1MEN1KMT2A | |
| SCHEMBL6609014 | 0.73 | KDM5A (0.34) | EPHX1DNM1MEN1FAAHKMT2A | |
| SCHEMBL1838870 | 0.73 | KDM5A (0.34) | EPHX1EPHX2DNM1MEN1FAAH | |
| SCHEMBL9456807 | 0.71 | CA1 (0.46) | EPHX1KDM5AKDM4C | |
| SCHEMBL7689399 | 0.70 | KDM5A (0.33) | NAAAEPHX1EPHX2DNM1MEN1 | |
| SCHEMBL7689401 | 0.70 | ADH1C (0.37) | EPHX1DNM1MEN1FAAHKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272677-A1 | Delivery of a substance to a pre-determined site | APPLIED NANOSYSTEMS B.V. (NL) | 2005-12-08 | — | — | US | disclosed |
| EP-1490028-A1 | DELIVERY OF A SUBSTANCE TO A PRE-DETERMINED SITE | Applied NanoSystems B.V. (NL) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084508-A1 | DELIVERY OF A SUBSTANCE TO A PRE-DETERMINED SITE | APPLIED NANOSYSTEMS B.V. (NL) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272677-A1 | Delivery of a substance to a pre-determined site | TACR1, TACR2, NPSR1 | NAAA 2681/4885EPHX1 639/4885EPHX2 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.